What to Watch in the Day Ahead - Friday, April 26
The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US. Thomson One users can register at RT/DAY/US. All times in ET/GMT
A report from the Commerce Department's Bureau of Economic Analysis is likely to show the personal consumption expenditures (PCE) price index likely rose 0.3% in March after a similar rise in the previous month. In the 12 months through March, PCE likely increased 2.6% after advancing 2.5% in February. Excluding the volatile food and energy components, the PCE price index is expected to rise 0.3% in March, following a similar rise in the month before. The so-called core PCE is expected to gain 2.7% on a year-on-year basis. Meanwhile, consumer spending is expected to have eased with a rise of 0.6% in March after jumping 0.8% in the previous month. Personal income likely grew 0.5% in March, following a 0.3% gain in the previous month. Separately, the University of Michigan's final reading on the overall index of consumer sentiment likely came in at 77.9 in April, unchanged from the previous month.
Oil major Exxon is expected to report first-quarter earnings per share of $2.16 compared with $2.79 a year ago on weaker natural gas prices, higher maintenance costs and derivatives, according to data from financial firm LSEG.
Chevron is expected to report lower first-quarter profits than last year due to weaker oil and gas prices and lower production. Investors will look for a full-year outlook and an update on Hess's acquisition.
Also, AbbVie is scheduled to report its first-quarter earnings. Investor focus is expected to be on the erosion of Humira sales and the growth of its newer immunology drugs, Skyrizi and Rinvoq.
Colgate-Palmolive is expected to post a rise in first-quarter revenue, helped by steady demand for its products including oral care and pet nutrition. Investors will look for comments on pricing actions, demand, impact of increasing competition and annual forecasts.
HCA Healthcare is set to report its first-quarter results before markets open. The focus will be on changes to its annual forecast and comments by the largest U.S. for-profit hospital operator on patient admissions and demand for medical procedures.
Phillips 66 is likely to post a profit decline due to weaker margins; however, tight supplies could boost its margins. Investors will look for any commentary on demand and refining operations.
Charter Communications is expected to post a rise in revenue in the first quarter as it sees steady subscriber growth from its rural expansion plans.
Aon will report higher first-quarter results, helped by the company's growing reliance on its reinsurance products and services.
Asset manager T Rowe Price is scheduled to report its first-quarter earnings. Thanks to a rebound in markets, analysts expect its profit to grow.
Software firm Roper Technologies is expected to report a rise in first-quarter revenue helped by strong IT spending by clients.
In Latin America, Brazil's IPCA-15 consumer price index for the first half of April likely rose 0.29%, following a 0.36% gain in the previous period. Annually, the index probably increased 3.86%. Separately, Mexico's national statistics agency is likely to show a surplus in trade at $700 million for the month of March, after posting a deficit of $585 million in the previous month. Meanwhile, Mexico's headline unadjusted unemployment rate is expected at 2.4% in March.
Compiled by Shreya Sabharwal in Bengaluru; Editing by Ravi Prakash Kumar
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
